{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-178836","form_type":"8-K","ticker":"RVMD","cik":"0001628171","company_name":"Revolution Medicines, Inc.","filed_at":"2024-07-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.864409+00:00","generated_at":"2026-05-31T20:42:39.260642+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Revolution Medicines guides 2024 net loss $560-600M; RMC-6236 shows 8.1-month PFS in 2L PDAC, Phase 3 planned","bullets":["Net loss for FY2024 expected $560-600M, including $70-80M non-cash stock-based comp.","Cash runway into 2027; current cash, equivalents, and marketable securities sufficient.","RMC-6236 in 2L metastatic PDAC: median PFS 8.1 months (KRAS G12X); ORR 27% (20+ weeks treatment).","Safety: 96% any-grade TRAEs, 22% Grade ≥3; 0% discontinuation; dose intensity 94%.","Plans to initiate randomized Phase 3 RASolute 302 in 2H 2024 vs investigator's choice chemo."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-178836","json":"https://secwatch.observer/filing/0001193125-24-178836.json","markdown":"https://secwatch.observer/filing/0001193125-24-178836.md","text":"https://secwatch.observer/filing/0001193125-24-178836.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1628171/000119312524178836/0001193125-24-178836-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1628171/000119312524178836/d869775d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T20:42:39.260642+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}